A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Ohio State University
Hoffmann-La Roche
Arvinas Inc.
Myeloid Therapeutics
xCures
DualityBio Inc.
Zhejiang University
Seagen Inc.